Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eight-Treg dose-escalation study in living-donor kidney transplant recipients
2024-513771-40-01Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Mar 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Eight Treg in chronic kidney disease (CKD) and kidney failure, sponsored by CHU de Nantes. Primary endpoint: Dose-limiting toxicity through 3 months post-graft. Planned start Mar 2025; status: authorised.
02
Drugs
Eight Treg
03
Conditions
chronic kidney disease (CKD)kidney failure
Beyond the preview
Go deeper on 2024-513771-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513771-40-01.